Analysis of a T cell receptor gene as a target of the somatic hypermutation mechanism by unknown
Analysis  of a  T  Cell  Receptor  Gene  as a  Target  of the 
Somatic  Hypermutation  Mechanism 
By John Hackett, Jr., Chris Stebbins,* Brian Rogerson,~  t 
Mark M.  Davis, S and Ursula Storb 
From the Department of Molecular Genetics and Cell Biology, The University of Chicago; the 
*Committee on Immunology, The University of Chicago, Chicago, Illinois 60637; the CTrudeau 
Institute, Saranac Lake, New York 12983; the gHoward Hughes Medical Institute and the 
Department of Microbiology and Immunology, Stanford University &hoot of Medicine, Stanford, 
California 94305-5402 
Summary 
In an effort to identify c/s-acting elements required for targeting of the somatic hypermutation 
process in mice, we examined whether a T  cell receptor (TCR)  transgene under the control 
of the immunoglobulin (Ig) heavy (H) chain intron enhancer would be mutated in antigen- 
stimulated B cells. Hybridomas were established from splenic B cells of mice carrying two copies 
of the TCR transgene after hyperimmunization with phosphorylcholine keyhole limpet hemocyanin. 
Northern analysis revealed that all of the transgene-containing hybridomas expressed the TCR 
mRNA.  Multiple somatic point mutations were found in seven of eight endogenous Ig VH 
genes examined. In contrast, 29 of 32 TCR genes examined contained no mutations. One potential 
mutation was seen in each of the three other TCR genes. Our data indicate that although the 
TCR transgene is expressed in B cells, it is not efficiently targeted by the mutator mechanism. 
Furthermore, the presence of an Ig H chain enhancer is itself not sufficient for targeting of the 
somatic hypermutation mechanism. 
S 
omatic hypermutation of Ig genes after antigenic stimu- 
lation of B cells is an important mechanism for diversi- 
fication of the immune repertoire (reviewed in 1, 2). The rate 
of antigen-induced somatic hypermutation of Ig V  region 
genes has been estimated at up to  10-Ubp/cell generation 
(3).  Although both productively and nonproductively rear- 
ranged V genes are targeted, constant regions are spared (4-7). 
This process appears to be unique to B cells, in that somatic 
hypermutation does not appear to play a significant role in 
diversification of TCR genes in T  cells. 
The molecular mechanism responsible for selectively in- 
troducing the characteristic single-base substitutions into Ig 
V regions and their flanking sequences is unknown. Although 
gene conversion appears  to play a critical role in generation 
of the immune repertoire in chickens (8, 9) and rabbits (It)), 
a significant role in somatic mutation of Ig genes in mice 
or humans has not been found (11, 12). The nature and local- 
ization of mutations in humans and mice are suggestive of 
a mechanism involving targeted point mutations (5, 13-17). 
We and others have shown that rearranged Ig transgenes 
can be targeted by the somatic hypermutation mechanism 
(17-21). The nature and localization of mutations are similar 
to those seen in endogenous Ig genes (20, 21). The ability 
of the mutator mechanism to target these Ig transgenes, in- 
dependent of their chromosomal location, suggests that they 
contain any required c/s-acting elements. In an effort to define 
potential targeting requirements of the somatic hypermuta- 
tion machinery, we examined whether a rearranged TCR gene, 
when expressed in B cells, would be targeted by the mutator 
mechanism. 
Materials and Methods 
Mice.  Generation of the 2B4/8-L mouse line carrying two copies 
of the 2B4/fE. transgene (see Fig. 1) has been described previously 
(22). 
Generation and Screening of Hybridomas.  A  2B4~-L transgenic 
mouse ([C57BL/6  ￿  C3H/HeJ]F2 backcrossed to C57BL/6) was 
immunized intraperitoneally with phosphorylcholine (PC)I-KLH 
as follows: 0.1 mg in CFA on day  -120, 0.1 nag in IFA on day 
-78, and 0.1 mg in PBS on days -53,  -3, and  -1, relative to 
fusion of spleen cells with the myeloma X63-AgS.653 as described 
(23). Hybridomas were screened by ELISA for secretion of IgM 
or IgG, PC-BSA binding  (18), and subsequently cloned by lim- 
iting dilution.  In cases where IgG subclass is indicated, this was 
Abbreviations used in this paper: E,, Ig heavy  chain enhancer; L, leader; 
PC, phosphorylcholine. 
225  J. Exp. Med. @ The Rockefeller  University  Press ￿9 0022-1007/92/07/0225/07 $2.00 
Volume 176  July 1992  225-231 determined by DNA sequencing. Determination of whether the 
hybridomas contained the transgene was carried out using PCK 
analysis (24).  Amplification of I #g of hybridoma DNA was per- 
formed with the primers 2B4-1 (5'd[AAACTGCAGGAAGTGTA- 
ATGAGGAAG]Y at position 28 (25), and 2B4-2 (5'd[GATGGATC- 
CGCTGAGAACGCGCACGTG]Y  at  position  604  in  100-#1 
reactions containing 50 mM KC1, 10 mM Tris-HC1 pH 8.3 (room 
temperature),  1.5 mM MgC12, 0.01%  (wt/vol) gelatin,  200/~M 
of each dNTP, 50 pmol of each primer, and 4 U Thermus  aquaticus 
(Taq) polymerase (Perkin Elmer Cetus Corp., Norwalk, CT). 32 
cycles of amplification were performed on a Twin block thermoey- 
clef (Ericomp Inc., San Diego, CA). Cycling steps were: denatura- 
tion,  1.5 rain at 94~  annealing, 2 rain at 55~  and extension, 
3  min at 72~ 
Northern Blot Analysis.  Northern blot analysis was performed 
with 20 #g of total RNA. To assay 2B4flE. transgene expression, 
blots were probed with a 574-bp fragment encompassing the VDJ 
region amplified with the primers 2B4-1 and 2B4-2 by PCR (see 
above), or with a 2.6-kb fragment containing the 2B4 VDJ region 
isolated from a genomic done. To monitor expression of the V1 
gene of the V.S107 family,  blots were probed with a 189-bp V.- 
167-specific  fragment (26). 
Nucleotide Sequencing.  For sequence  analysis of endogenous V. 
genes, total RNA was prepared by the guanidine isothiocyanate 
method (27).  First-strand DNA synthesis was carried out using 
the  primers  X'y 5'd[GGGGCCAGTGGATAGAC]Y and  3"3  5' 
d[AGGGACCAAGGGATAGAC]3; specific for the CH1 domains 
of all IgG subclasses  or M-CH1  5' d[GCTCTCGCAGGAGAC- 
GAGGGGGAAG]Y, specific for the CHI domain of lgM.  The 
cDNA was generated in a 10-/xl reaction containing 3-5/~g KNA, 
10 pmol primer (3'3  +  X3" or M-CH1) using avian myeloblastosis 
virus (AMV) reverse transcriptase (Boehringer Mannheim,  Indi- 
anapolis, IN) at 42~  for 70 min, then heated at 65~  for 20 min. 
PCR amplification of the V. segments was carried out using the 
degenerate  leader  region  primers  MH-SP-ALT.1  5'd[ATG(GA)- 
A(GC) TT(GC)(TG)GG(TC)T(AC)A(AG)CT(GT)G(GA)TT]Y 
and MH-SP-ALT.2 5'd[ATG(GA)AATG(GC)A(GC)CTGGGT(CT)- 
(TA)T(TC)CTCT]Y (28),  along with the "/3 and X3" primers or 
M-CH1. A mix containing PCR buffer, 50 pmol of each primer, 
and 4 U  Taq polymerase was added to the 10-#1 cDNA reaction 
to bring the total volume to 100 #1. A 25-cycle amplification was 
carried out on a GeneAmp 9600 (Perkin Elmer Cetus Corp.) with 
denaturation  at 94~  for 30 s, annealing at 50~  for 30 s,  and 
extension at 72~  for 60 s. Amplification products were isolated 
on 1% low-melt agarose (FMC Corp., Rockland, ME) gels, and 
blunt-end  cloned into EcoRV-digested pBluescript  KS + (Strata- 
gene Inc., La Jolla, CA). CsCl-banded plasmid DNA or miniprep 
DNA prepared with Qiagen tip-20 columns (Qiagen, Inc., Chat- 
sworth, CA) was alkali denatured and annealed to KS or SK primers 
(Stratagene Inc.). Sequencing was performed using the Sequenase 
kit (US Biochemicals, Cleveland,  OH). 
To sequence the 2B43E. transgenes, hybridoma DNA (40 #g) 
was digested with BamHI, and electrophoresed on 1% low-melt 
agarose gels to separate the two copies of the transgene L-VDJ 
region. Agarose blocks corresponding to the 2.8-3.5- and 6.0-16.0- 
kb regions were excised and melted at 65~  A 574-bp fragment 
encompassing the transgene L-VDJ region was amplified by PCR 
using the primers 2B4-1 and 2B4-2, as previously described (17). 
25 cycles of amplification were performed on a GeneAmp 9600 with 
denaturation  at 94~  for 15 s,  annealing at 55~  for 30 s,  and 
extension at 72~  for 60 s. The PCK products were cloned and 
sequenced  using  the  primer  2B4-3  5'd[CACTCAGCAGAGAA- 
TCG]Y at position 436 of the 2B4 transgene (25),  in addition to 
VDJ  C~2 
E  H 
I  ! 
!  kb 
Figure  1.  Diagram of the 2B43E. transgene. The rearranged genomic 
13 chain clone contains 4.5 kb 5' sequence and 3.0 kb of 3' flanking se- 
quence. A 687-bp fragment containing the Ig H chain J-C intron enhancer 
was introduced into a ClaI site 3  ~  of the VDJ region (22). B =  BamHI. 
KS and SK primers as previously outlined.  In an effort to distin- 
guish between  somatic mutations and Taq polymerase errors, if 
potential  mutations  were identified,  additional  products  of the 
original PCR were examined, or products from a second, indepen- 
dent, PCK reaction were sequenced. Alterations were considered 
to be actual mutations if they were still present in products of the 
second PCR reaction. 
Results  and  Discussion 
To define potential targeting requirements of the somatic 
hypermutation mechanism, we utilized the transgenic mouse 
line 2B4fl-L.  The 2B4B-L line carries  a low copy number 
of a rearranged genomic TCR-fl chain construct  that lacks 
the native TCR-3 enhancer region (29-31), but contains an 
Ig  H  chain  enhancer  (E.)  element  between  J  and  Cfl2 
(2B43E.,  Fig.  1, reference 22).  2B43-L mice were hyperim- 
munized  with  PC-KLH,  and  spleen  B  cells were fused  to 
Table  1.  Properties  of the Hybridomas 
PC-BSA  Isotype  Transgene  V1  Expression* 
10C8  +  IgM  +  - 
10F4  +  IgG  -  ND 
1A2  +  IgM  +  - 
1A6  +  IgG1  +  + 
1E1  +  IgM  +  + 
1H2  §  IgG1  +  + 
2E2  -  IgG2b  +  - 
2F12  +  IgM  +  - 
3G5  +  IgG1  +  + 
4C2  +  IgG1  +  + 
4G6  +  IgG  +  - 
4G7  +  IgG  +  ND 
5D10  +  IgG1  +  + 
8Dll  -  IgG  +  - 
8E2  +  IgG1  +  + 
8G1  +  IgG2a  +  + 
3A 11  +  IgG  +  - 
* Expression of the V1 gene of the $107 family was assessed by probing 
Northern blots with a V.-167-specific fragment. 
226  Specificity  of the Somatic Hypermutation  Mechanism Figure  2.  Northern analysis of 2B43E~ expression. Blot A was probed with a PCR-generated probe containing the 2B4 VDJ region. Blot B was 
probed with a genomic clone encompassing the 2B4 VDJ region. RNA from spleen 2203 and thymus 2105 were from 2B43-L  transgenic mice. Spleen 
R.NA from a C57BL/6 mouse and the myeloma X63-Ag8.653  served as negative controls. Hybridoma clones 101=4.1 and 10F4.2, both derived from 
the same hybridoma line, do not contain the transgene (see Table I). Based on ethidium bromide staining of the gel before blotting,  rRNA quantities 
were roughly  equal in all lanes. 
the nonsecreting line X63-Ag8.653  to generate hybridomas. 
An  advantage  of this antigen  system is that the majority of 
PC-specific  antibodies  utilize  the  V1  gene  of  the  V.$107 
family  (32),  providing  a means  of monitoring  whether  the 
mutator mechanism has been active in the fused B  cells.  Fur- 
thermore,  selection of IgG  secreting hybridomas  should in- 
crease  the  likelihood  of analyzing  B  cells  in  which  the  so- 
matic hypermutation mechanism has been active. Hybridoma 
dones were screened for IgG and IgM production and binding 
to PC coupled to BSA. Properties of hybridoma clones selected 
for study are shown in Table 1. 13 of the 17 hybridomas secreted 
IgG,  and  15  of  17  bound  PC-BSA.  PCK  analysis  revealed 
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Figure  3.  Sequence  analysis of endogenous V. genes. Only hybridomas expressing the V1 gene of the $107 family are shown. Codons of the germ- 
line C57BL/6 V1 gene (35), in which mutations were observed, are shown. Bases in upper case letters indicate mutations leading to amino acid replace- 
ments. Lower case letters represent silent substitutions. (Boxed) CDKs.  With the exception of 4C2,  all mutations were verified by two independent 
cDNA  and PCK reactions. 
227  Hackett et al. that the 10F4 subclones had lost the transgene, and these were 
eliminated from further analysis. 8 of 16 hybridomas carrying 
the transgene expressed  the V1  gene of V.$107 based  on 
Northern  analysis  (data not  shown)  or RNA  sequencing 
(Fig. 3). 
In previous experiments, the addition of an E. element to 
a TCR-ot chain construct resulted in the expression  of this 
ot chain in transfected plasmacytoma (J558L) cells (33). Fur- 
thermore, in experiments with transgenic mice carrying this 
TCR-ot chain gene under the control of the E., it was ex- 
pressed in splenic B cells (33). Consistent with these findings, 
Northern analysis revealed that the 1.3-kb B chain transcript 
is present in all B cell hybridomas that retained the 2B4/~E. 
transgene, as well as in spleen and thymocyte  RNAs of  2B4/~-L 
mice (Fig. 2). Thus, the E. control element provides for ex- 
pression of the TCtL-B chain construct in B cells, as well as 
in T  cells. 
To establish  whether the mutator mechanism was active 
in the B cells before fusion, we examined endogenous V. 
genes expressed by the hybridomas. Primers specific for the 
CH1 domain of IgM or IgG were used to specifically prime 
first-strand DNA synthesis.  These products were amplified 
by pcp,, cloned, and sequenced  (Fig. 3). Only hybridomas 
using the V1 gene of the V8S107 family are shown. Since 
there are only four members in the $107 family (32),  muta- 
tions of V1 can be scored with greater confidence than V 
genes in the larger V. families. In all cases, cloned V1 genes 
contain the allelic substitutions found in the C57BL/6 germ- 
line gene (34, 35). Seven of the eight expressed V1 genes were 
mutated, with the number of mutations ranging from 3-11. 
A  total of 52 single base substitutions were observed  over 
a total of 2.4 kb analyzed. In a few cases, mutations were 
shared between V1 genes in different hybridomas. It is con- 
ceivable  that  some  (but  not  all)  of these  may represent 
C3H/HeJ allelic differences, as the germline sequence has not 
been determined. Clearly, the mutator mechanism had been 
active in the majority of the B cells before fusion. 
To determine if the TCR transgene was mutated, a 574- 
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Figure 4.  Sequence  analysis  of 2B4BE~ transgenes. 
The amplified  region  is depicted schematically.  (Solid 
line) The region sequenced. Clones of copy 1 from 
the hybridomas  2F12 and 5D10 have  small  sequencing 
gaps extending  from 364-383 and 373-403, respec- 
tively. All TCR clones (including  those  amplified  from 
kidney  DNA) contained  the following  alterations  from 
the published sequence (25): T at 88, A at 116, A at 
120, C at 150, as previously  noted  in a V~3 clone  from 
C57BL/6  (42). The amplified  L-VDJ region corre- 
sponding to the 7.5-kb BamHI  fragment  (designated 
copy 1) in all hybridomas  (and transgenic  kidney)  has 
a C~T substitution  at position 227 ([]) within the 
L-V intron. (X or X) Alterations  from the germline 
sequence which were confirmed  by sequencing  prod- 
ucts of a second PCR (see text). Clones of copy 1 in 
hybridomas  1H2 and 4G6 contain  an A--~G substitu- 
tion at position  43. Copy  1 in 8G1 has a G~A substi- 
tution at position 508. 
228  Specificity  of the Somatic Hypermutation  Mechanism bp fragment encompassing the 2B4/3E. I_,VDJ region (Fig. 
4) was amplified from hybridoma DNA by PCR,  cloned, 
and sequenced. This region was chosen because in K trans- 
genes the analogous region was heavily targeted by the so- 
matic hypermutation process (17, 20, 21). Preliminary anal- 
ysis of 2B4B-L transgenic DNA revealed that there are two 
copies of this target region. In all cases, including transgenic 
kidney DNA, clones were generated that contained a T  at 
position 227 within the L-V intron, in addition to clones with 
a C (published sequence, 25) at this position. BamHI diges- 
tion  and Southern  analysis  revealed two single-copy bands 
hybridizing to the 2B4/3 VDJ and E. probes, one at the ex- 
pected  7.5-kb  range  and  one  at  3  kb  (data  not  shown). 
Whether the smaller fragment has arisen because of a muta- 
tion leading to introduction  of a new BamHI site (which 
might have occurred during transgene integration), or whether 
it represents  a partial  copy, has not been determined.  The 
orientation  of the two copies relative to each other is un- 
known.  Amplification  of the  separated fragments  demon- 
strated that the larger fragment (copy 1), contains a T at 227, 
while the smaller fragment (copy 2) has a C at this position. 
This substitution proved useful in distinguishing the cloned 
transgene  products. 
29 of 32 total TCR L-VDJ regions analyzed contained no 
mutations (Fig. 4). Copy I cloned from hybridomas 1H2 and 
4G6 contained a single mutation (A~G) at position 43, 5' 
of the L  sequence.  This identical  substitution  was seen in 
products of four other hybridomas, but was determined to 
be a PCR or cloning artifact, as it was not present in prod- 
ucts of another PCR from these four hybridomas. Thus, the 
significance of this  substitution  in copy 1 from these two 
hybridomas is unknown, but we consider it likely that this 
position may represent a hot spot for PCR errors.  Copy 1 
cloned from 8G1 contained a single mutation (G---A) at po- 
sition 508.  This substitution was seen in products of three 
independent PCR amplifications of 8G1 DNA, and thus ap- 
pears to be a somatic mutation, as it was not present in kidney 
DNA or the other  hybridomas. 
Thus, in 17.5 kb of TCR sequence examined (two copies 
from 16 different hybridomas), only three potential somatic 
mutations have been identified.  Of these,  two are an iden- 
tical substitution found at the same position.  If this altera- 
tion is somatic in nature,  it is conceivable that  it occurred 
early in B cell development, before the onset of somatic hyper- 
mutation,  and is  shared by progeny of this clone. 
In any case, the frequency of mutations in the TCR genes 
(0.017% if all three substitutions are included) is markedly 
reduced  as  compared  with  that  seen  in  the  expressed V. 
genes (2.1%).  These data indicate that  although  the TCR 
/3 chain gene is expressed in B cells, it is not efficiently tar- 
geted by the somatic hypermutation  mechanism. 
In contrast to B cells, evidence of somatic hypermutation 
has not been documented in T cells. These data suggest that 
TCK genes do not contain cis-acting elements required for 
recognition by the mutator mechanism.  However, it is not 
known whether the mutator mechanism is ever activated in 
T  cells.  Most likely it is not,  and the lack of observed so- 
matic mutations in TCR V genes could be due to the com- 
bined absence of cis-acting  elements  and the mutator. 
One trivial explanation for the observed lack of targeting 
of this TCK gene by the mutator  mechanism  could be an 
inhibitory effect of the transgene insertion site. However, the 
ability to demonstrate expression of the transgene suggests 
that it should be accessible to the mutation process. In mul- 
tiple cases where ~ or H transgenes have been examined, they 
have functioned as substrates for the mutation process (17-21). 
These data are consistent with the notion that targeting of 
Ig transgenes can occur independent  of chromosomal loca- 
tion, as long as they are accessible to the mutator mechanism. 
An Ig H  chain  transgene containing  only the intron  E. 
appears to function as a substrate for the somatic hypermuta- 
tion mechanism (19). However, based on our data, although 
the Ig E. element may be required for somatic mutation,  it 
is not sufficient to provide efficient targeting of the mutator 
mechanism. This is interesting, as truncated ~ transgene con- 
structs lacking the 3' K enhancer  (36) do not appear to be 
targeted for somatic hypermutation (37, 38), even if expressed 
at high levels (38).  This suggested a cis-acting role for the 
3' enhancer element in the process. Whether  it is required 
for actual recognition of the Ig substrate by the mutator mech- 
anism, or is important  for maintaining  transcription  of the 
gene while the mutator mechanism  is active, is unknown. 
Recent analysis  of the localization  pattern  of mutations 
in endogenous K and H genes and in multi-copy K transgenes 
(17,  20, 39-41) have led to the suggestion that  critical cis- 
acting elements may be located 5' to the V genes. Conceiv- 
ably, the TCR gene differs in this upstream region in a se- 
quence which is essential for targeting the mutation process. 
The TCR construct used in this study included 4.5 kb of 
genomic sequence upstream  of the leader.  It would be in- 
teresting to see if the introduction  of 5' K sequences would 
make this TCR gene a substrate for somatic hypermutation. 
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